Atherogenics ist in den letzten Wochen von 2 us Cent auf 16 us Cent gelaufen.angeblich ist Pfizer an einer übernahme interessiert.mehr Informationen liefert das yahoo board.denke wir sehen bald die 25 us Cent.ein Zock wie leh und wamu.es ist von Kursen ueber 1 Dollar die Rede.wenn kaufen dann in den usa.die Taxe hier ist lachhaft.
Übernahmefantasie treibt den Kurs
Beiträge: 16
Zugriffe: 3.460 / Heute: 1
Zugriffe: 3.460 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +41,91%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +41,85%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +39,12%
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +38,43%
SPDR MSCI Europe Technology UCITS ETF
Perf. 12M: +32,71%
Agix hat andes mit einem Marktpotential von bis zu 20 Milliarden
aus dem i-hub
The model for big pharma is to partner with smaller biotechs at 100-400 mil per deal doing 10-20 deals to spread their risk in the disease area of interest.
1. Diabetes is a known market and there is a huge void for folks that can't be controlled on current treatment!
2. THis fits the bill of that 100-400 bet and allows one not to blow your whole wad on a big deal. A 300-400 mil bet on phase three data and to own product 100% is a steal.
3. We had a look at the phase 3 data so we know pretty much what we have!
Most of these deals in the 100-400 million range give a company 60% rights to the product and they have to pay additional money for development of the product. At 300-400 mil it is a steal. If it goes for below 300 then it is highway robbery. Lets just hope the judge see it this way!!!!!!!!!!!!!!!!!!!
I say the stock will go up to 1.75 to 3.50 on buyout making AGIX the best stock of the year!!!!!!!!!!!!!!!!!!!!
All of you dooms dayers will be crying should of would of could of bought more and held!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
The model for big pharma is to partner with smaller biotechs at 100-400 mil per deal doing 10-20 deals to spread their risk in the disease area of interest.
1. Diabetes is a known market and there is a huge void for folks that can't be controlled on current treatment!
2. THis fits the bill of that 100-400 bet and allows one not to blow your whole wad on a big deal. A 300-400 mil bet on phase three data and to own product 100% is a steal.
3. We had a look at the phase 3 data so we know pretty much what we have!
Most of these deals in the 100-400 million range give a company 60% rights to the product and they have to pay additional money for development of the product. At 300-400 mil it is a steal. If it goes for below 300 then it is highway robbery. Lets just hope the judge see it this way!!!!!!!!!!!!!!!!!!!
I say the stock will go up to 1.75 to 3.50 on buyout making AGIX the best stock of the year!!!!!!!!!!!!!!!!!!!!
All of you dooms dayers will be crying should of would of could of bought more and held!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial Of AGI-1067 In Type 2 Diabetes
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced top-line results from its ANDES Phase 3 clinical trial of AGI-1067 (succinobucol) for the treatment of Type 2 diabetes demonstrating that both doses (75mg and 150mg) of AGI-1067 met the primary efficacy endpoint of the reduction in glycosylated hemoglobin (A1c) versus placebo at the end of the study's six month dosing regimen.
"We are pleased that the ANDES trial met the primary endpoint and showed a dose response in reducing A1c. Based on the results of this successful trial, AtheroGenics intends to rapidly move forward with development of AGI-1067," said Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics. "We believe that AGI-1067, through its unique mechanism of action, could become the first diabetes treatment with demonstrated cardiovascular safety, and with the potential to reduce cardiovascular hard events including cardiovascular death, heart attack and stroke, as reported from the 6,144 patient Phase 3 ARISE trial, which concluded in 2007."
ANDES, an international, double-blind trial, showed a dose-dependent, statistically significant drop in A1c of 0.6% and 0.4% in the 150mg and 75mg arms, respectively, at 6 months, compared to baseline (p < 0.001 for 150 mg versus placebo, p = 0.016 for 75 mg versus placebo). The placebo group decreased 0.2% from baseline.
In the trial, a regional variation was observed in the placebo arm. Eastern Europe showed a significant decrease of 0.5% for A1c in the placebo arm versus baseline. The other study regions showed an increase of 0.1% in A1c in the placebo arm versus baseline. Importantly, A1c reductions in both AGI-1067 treatment arms were similar across all of the regions in the study. The study analysis plan was prospectively designed to detect and analyze the effect of regional differences. AtheroGenics will continue to analyze the trial data, including the impact of regional differences.
Based on a preliminary review of the safety data, AGI-1067 was well-tolerated and was not associated with weight gain or hypoglycemia in either of the treatment groups. There was no difference in discontinuations between the groups receiving active drug and placebo. One patient in the 150mg arm and two patients in the 75mg arm had unexplained liver enzyme elevations of greater than five times the upper limit of normal. The liver enzyme elevations either have resolved or are resolving.
The Company also announced today that it has developed a patient identification tool to screen for the small number of patients who are potentially at risk for adverse hepatic effects that have been observed during treatment with AGI-1067. The tool has performed well at identifying at-risk diabetes patients across all doses used in the ARISE and ANDES trials.
"We are excited about the advances we have made to date with the patient identification tool for AGI-1067," commented Alexander Fleming, M.D., Acting Chief Medical Officer. "We plan to incorporate this tool into the next AGI-1067 Phase 3 trial."
About ANDES
The data represent findings from a multinational, double-blind, placebo-controlled, dose-finding study of patients with Type 2 diabetes (ages 18-75) who were on one or no other oral anti-diabetes therapies and whose A1c level was greater than or equal to 7.5% and less than or equal to 10.5% and completed the study. A total of 999 patients were enrolled in the ANDES study, including 887 in the current three-arm protocol. The trial included approximately 150 clinical sites in the United States, South Africa, India and Eastern Europe.
About AGI-1067
AGI-1067 is a novel oral drug candidate with demonstrated anti-inflammatory and antioxidant properties. AGI-1067 works by selectively inhibiting signaling pathways that are activated in response to oxidative stress and pro-inflammatory stimuli. Oxidative stress and inflammation have been implicated as playing a key role in the pathogenesis of insulin resistance and diabetes.
About Type 2 Diabetes
Diabetes (diabetes mellitus) is a chronic disease in which the body does not produce enough insulin (insulin deficiency), or the cells ignore the insulin (insulin resistance). Insulin is a hormone that is needed to convert sugar and starches (carbohydrates) into energy needed for daily life. The cause of diabetes continues to be investigated, and both genetic and environmental factors such as obesity and lack of exercise appear to play a role. The disease may lead to blindness, heart disease, stroke, kidney failure, amputations and nerve damage. Type 2 (adult onset) diabetes accounts for approximately 90 to 95 percent of all diabetes. This equates to roughly 221 million people with type 2 diabetes globally, and 24 million people in the U.S. alone. The American Diabetes Association recommends an A1c measurement of less than 7% for most people with Type 2 diabetes. A1c is a measurement of a person's average blood glucose level over a two-to-three month period and is considered an important marker of long-term glucose control.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being studied for the treatment of diabetes and has completed a Phase 3 clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study). In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection.
AtheroGenics
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced top-line results from its ANDES Phase 3 clinical trial of AGI-1067 (succinobucol) for the treatment of Type 2 diabetes demonstrating that both doses (75mg and 150mg) of AGI-1067 met the primary efficacy endpoint of the reduction in glycosylated hemoglobin (A1c) versus placebo at the end of the study's six month dosing regimen.
"We are pleased that the ANDES trial met the primary endpoint and showed a dose response in reducing A1c. Based on the results of this successful trial, AtheroGenics intends to rapidly move forward with development of AGI-1067," said Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics. "We believe that AGI-1067, through its unique mechanism of action, could become the first diabetes treatment with demonstrated cardiovascular safety, and with the potential to reduce cardiovascular hard events including cardiovascular death, heart attack and stroke, as reported from the 6,144 patient Phase 3 ARISE trial, which concluded in 2007."
ANDES, an international, double-blind trial, showed a dose-dependent, statistically significant drop in A1c of 0.6% and 0.4% in the 150mg and 75mg arms, respectively, at 6 months, compared to baseline (p < 0.001 for 150 mg versus placebo, p = 0.016 for 75 mg versus placebo). The placebo group decreased 0.2% from baseline.
In the trial, a regional variation was observed in the placebo arm. Eastern Europe showed a significant decrease of 0.5% for A1c in the placebo arm versus baseline. The other study regions showed an increase of 0.1% in A1c in the placebo arm versus baseline. Importantly, A1c reductions in both AGI-1067 treatment arms were similar across all of the regions in the study. The study analysis plan was prospectively designed to detect and analyze the effect of regional differences. AtheroGenics will continue to analyze the trial data, including the impact of regional differences.
Based on a preliminary review of the safety data, AGI-1067 was well-tolerated and was not associated with weight gain or hypoglycemia in either of the treatment groups. There was no difference in discontinuations between the groups receiving active drug and placebo. One patient in the 150mg arm and two patients in the 75mg arm had unexplained liver enzyme elevations of greater than five times the upper limit of normal. The liver enzyme elevations either have resolved or are resolving.
The Company also announced today that it has developed a patient identification tool to screen for the small number of patients who are potentially at risk for adverse hepatic effects that have been observed during treatment with AGI-1067. The tool has performed well at identifying at-risk diabetes patients across all doses used in the ARISE and ANDES trials.
"We are excited about the advances we have made to date with the patient identification tool for AGI-1067," commented Alexander Fleming, M.D., Acting Chief Medical Officer. "We plan to incorporate this tool into the next AGI-1067 Phase 3 trial."
About ANDES
The data represent findings from a multinational, double-blind, placebo-controlled, dose-finding study of patients with Type 2 diabetes (ages 18-75) who were on one or no other oral anti-diabetes therapies and whose A1c level was greater than or equal to 7.5% and less than or equal to 10.5% and completed the study. A total of 999 patients were enrolled in the ANDES study, including 887 in the current three-arm protocol. The trial included approximately 150 clinical sites in the United States, South Africa, India and Eastern Europe.
About AGI-1067
AGI-1067 is a novel oral drug candidate with demonstrated anti-inflammatory and antioxidant properties. AGI-1067 works by selectively inhibiting signaling pathways that are activated in response to oxidative stress and pro-inflammatory stimuli. Oxidative stress and inflammation have been implicated as playing a key role in the pathogenesis of insulin resistance and diabetes.
About Type 2 Diabetes
Diabetes (diabetes mellitus) is a chronic disease in which the body does not produce enough insulin (insulin deficiency), or the cells ignore the insulin (insulin resistance). Insulin is a hormone that is needed to convert sugar and starches (carbohydrates) into energy needed for daily life. The cause of diabetes continues to be investigated, and both genetic and environmental factors such as obesity and lack of exercise appear to play a role. The disease may lead to blindness, heart disease, stroke, kidney failure, amputations and nerve damage. Type 2 (adult onset) diabetes accounts for approximately 90 to 95 percent of all diabetes. This equates to roughly 221 million people with type 2 diabetes globally, and 24 million people in the U.S. alone. The American Diabetes Association recommends an A1c measurement of less than 7% for most people with Type 2 diabetes. A1c is a measurement of a person's average blood glucose level over a two-to-three month period and is considered an important marker of long-term glucose control.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being studied for the treatment of diabetes and has completed a Phase 3 clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study). In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection.
AtheroGenics
Zock Zock an der Börse wir dnur noch gezockt.
Die besten Börsenbriefe:
www.ariva.de/Boersenbriefe_t360882?page=0#jump5245522
www.ariva.de/Boersenbriefe_t360882?page=0#jump5245522
... ein Witzbold hat den Spread von 5800% genutzt um für kleines Geld berühmt zu werden :-)
Nasdaq OTC Other 5.000 0,02 $ 0,03 $ 5.000 50,00% 13:53:44
Frankfurt 1.000.000§0,001 € 0,059 € 16.950 5,80 T% 14:09:40
Und ich sach der Vouchel is dout!
Nasdaq OTC Other 5.000 0,02 $ 0,03 $ 5.000 50,00% 13:53:44
Frankfurt 1.000.000§0,001 € 0,059 € 16.950 5,80 T% 14:09:40
Und ich sach der Vouchel is dout!
(Verkleinert auf 81%) 
DIE FOLGENDEN AKTIEN SIND AB SOFORT AUSGESETZT:
THE FOLLOWING SHARES ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
Hisense Kelon Elec. HLD GKE CNE100000353 BAW/UFN
Atherogenics Inc. AG1 US0474391044 BAW/UFN
Eden Bioscience Corp. EBIB US2794458784 BAW/UFN
www.finanznachrichten.de/...b-aussetzungen-suspensions-029.htm
THE FOLLOWING SHARES ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
Hisense Kelon Elec. HLD GKE CNE100000353 BAW/UFN
Atherogenics Inc. AG1 US0474391044 BAW/UFN
Eden Bioscience Corp. EBIB US2794458784 BAW/UFN
www.finanznachrichten.de/...b-aussetzungen-suspensions-029.htm
Keine Kauf Empfehlung!!
Das Warten ist die grausamste Vermengung von Hoffnung und Verzweiflung, durch die eine Seele gefoltert werden kann.
Devise: "Kaufen, wenn alle anderen verkaufen"
Das Warten ist die grausamste Vermengung von Hoffnung und Verzweiflung, durch die eine Seele gefoltert werden kann.
Devise: "Kaufen, wenn alle anderen verkaufen"
www.finanznachrichten.de/...nnta-einstellung-delisting-029.htm
Keine Kauf Empfehlung!!
Das Warten ist die grausamste Vermengung von Hoffnung und Verzweiflung, durch die eine Seele gefoltert werden kann.
Devise: "Kaufen, wenn alle anderen verkaufen"
Das Warten ist die grausamste Vermengung von Hoffnung und Verzweiflung, durch die eine Seele gefoltert werden kann.
Devise: "Kaufen, wenn alle anderen verkaufen"
Hallo kann mir jemand sagen was mit ATHEROGENICS INC ist. Sie wurde ausgestzt aber wie weiter?
Neueste Beiträge aus dem ATHEROGENICS INC Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 15 | Übernahmefantasie treibt den Kurs | Andreano | rnietlispach | 04.08.09 18:53 | ||
6 | 325 | Megarebound könnte folgen wenn.. | Superflach | Andreano | 07.01.09 05:32 | |
| 2 | 10 | Faktenthread und Linksammlung zu AGIX | Superflach | kadmon | 04.06.08 14:51 | |
| ATHEROGENICS INC (WKN: 936248 kaufenswert) | wikki 1 | 04.02.08 20:56 |